| Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. | |
| | |
MedLine Citation:
|
PMID: 23275304 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Absence of, or loss-of-function mutations in the dysferlin gene (dysf) result in dysferlinopathy, characterized by increased muscle inflammation, collagen deposition and deterioration in muscle function. We evaluated halofuginone efficacy in improving muscle histopathology in mice with deleted dysf transmembrane domain. Quadriceps sublumbar and longissimus muscles of 9-month-old dysf-/- mice treated with halofuginone for 4 months exhibited a reduction in centrally-nucleated myofibers, inflammatory infiltrates and collagen content. Late onset of dysferlinopathy makes it ideal for evaluating the efficacy of early treatments on late outcome. The dysf-/- mice were treated with halofuginone for 3 to 4 months starting at 1, 5 or 9 months of age, and quadricep muscle histopathology was evaluated at 12 months. Collagen content and number of centrally nucleated myofibers decreased after early halofuginone treatment, administered when myofibers with central nuclei and inflammatory infiltrates are evident, but there was almost no fibrosis. When administered at the beginning of fibrosis it resulted in a further decrease in the number of centrally-nucleated myofibers with no additional decrease in collagen levels. Cardiac fibrosis was almost completely abolished following early halofuginone treatment. Halofuginone inhibited Smad3 phosphorylation and its translocation to the nucleus and increased the activity of matrix metalloproteinases 9 and 2 responsible for resolution of pre-existing collagen. Macrophage and myofibroblast invasion into the dystrophic muscle at the site of myofibers with central nuclei was inhibited by halofuginone. These results suggest that early halofuginone treatment can prevent the late outcome of dysferlinopathy and can cause resolution of the established fibrosis when administered at later stages. |
| | |
Authors:
|
O Halevy; O Genin; H Barzilai-Tutsch; Y Pima; O Levi; I Moshe; M Pines |
Related Documents
:
|
10962064 - Burrowing in the antarctic anemone, halcampoides sp., from signy island, antarctica. 9655694 - Origin of molecular species of diacylglycerol induced by bombesin in smooth muscle cell... 1917734 - Differences between vo2 maxima of twitch and tetanic contractions are related to blood ... 22063894 - Biochemical and physical factors affecting discoloration characteristics of 19 bovine m... 7397754 - Localization of adenylate cyclase in the neurointermediate lobe of the rat pituitary. u... 18937524 - The inflammatory response to skeletal muscle injury: illuminating complexities. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Histology and histopathology Volume: 28 ISSN: 1699-5848 ISO Abbreviation: Histol. Histopathol. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2012-12-31 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8609357 Medline TA: Histol Histopathol Country: Spain |
Other Details:
|
Languages: eng Pagination: 211-26 Citation Subset: IM |
Affiliation:
|
Department of Animal Sciences, the Hebrew University of Jerusalem, Rehovot, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pulmonary toxicity of instilled cadmium-doped silica nanoparticles during acute and subacute stages ...
Next Document: Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer.